Govt Tightens Surveillance on GLP-1 Weight Loss Drugs Amid Misuse Concerns

In a move to ensure ethical practices in the pharmaceutical sector, the Drugs Controller of India has intensified regulatory surveillance over the supply chain of GLP-1-based weight loss drugs.
 

The action comes amid rising concerns over the increasing availability of these drugs through retail pharmacies, online platforms, wholesalers, and wellness clinics. With several generic versions recently entering the Indian market, authorities have flagged the risk of misuse, especially when these medications are consumed without proper medical supervision.
 

Health experts warn that unsupervised use of GLP-1 drugs can lead to serious side effects and potential health complications.
 

Taking note of the situation, the national drug regulator, in coordination with State authorities, has launched targeted enforcement measures to curb unauthorized sales, misleading promotions, and improper prescription practices.
 

On March 10, 2026, a detailed advisory was issued to all manufacturers, strictly prohibiting surrogate advertising and any indirect promotion that could mislead consumers or encourage off-label use.
 

Enforcement efforts have been significantly ramped up in recent weeks. Authorities conducted audits and inspections at 49 entities, including online pharmacy warehouses, drug wholesalers, retailers, and wellness or slimming clinics across multiple regions. Notices have been issued to those found violating norms.
 

The regulator reiterated that patient safety remains the top priority. Citizens have been advised to use such medications only under the supervision of qualified medical professionals.
 

Importantly, GLP-1 drugs in India are approved strictly for use under prescription by specialists such as endocrinologists and internal medicine experts, and in certain cases, cardiologists.
 

The government has made it clear that surveillance will continue to intensify, and strict action—including license cancellation, penalties, and legal prosecution—will be taken against any non-compliance.